Literature DB >> 25372587

Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia.

Marilza Leal Nascimento1, Anísia Nhelety Baptista Cristiano2, Tatiane de Campos1, Masanao Ohira2, Edson Cechinel1, Genoir Simoni1, Juliana van de Sande Lee1, Rose Marie Muller Linhares1, Paulo Cesar Alves da Silva1.   

Abstract

OBJECTIVE: Evaluate the Neonatal Screening Program (NSP) for congenital adrenal hyperplasia (CAH) of the Department of Health of the State of Santa Catarina (Secretaria de Estado da Saúde de Santa Catarina, SES/SC), and provide information to improve the program. SUBJECTS AND METHODS: Descriptive, retrospective study of 748,395 children screened between January 2001 and December 2010. We analyzed the coverage of the NSP-SES/SC prevalence of CAH, child's age when the first sample for 17-hydroxyprogesterone (17OHP) measurement was collected, levels of 17OHP, mean age at treatment onset and main clinical manifestations.
RESULTS: The NSP-SES/SC covered 89% of the live newborns in the State. It diagnosed 50 cases of CAH, yielding an incidence of 1:14,967. Mean age at collection of the first sample was 7.3 days and mean level of 17OHP was 152.9 ng/mL. The most frequent manifestations were virilized genitalia with nonpalpable gonads, clitoromegaly and genital hyperpigmentation. In three girls, the genre established at birth was incorrect. The salt-wasting form was present in 74% of the cases. There was no occurrence of shock or death. Mean age at treatment onset in the salt-wasting form was 17.4 days compared with 54.9 days in those without the salt-wasting form of the disease. All children were treated with hydrocortisone, and those with salt-wasting CAH were also treated with fludrocortisone.
CONCLUSIONS: The incidence of CAH was 1 case to 14,967 live newborns. Collection of the first sample occurred outside the recommended time, resulting in delays in treatment onset.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25372587     DOI: 10.1590/0004-2730000003310

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  6 in total

1.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 2.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

3.  Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.

Authors:  Cristiane Kopacek; Simone Martins de Castro; Mayara Jorgens Prado; Claudia Maria Dornelles da Silva; Luciana Amorim Beltrão; Poli Mara Spritzer
Journal:  BMC Pediatr       Date:  2017-01-17       Impact factor: 2.125

4.  Pregnanetriolone in paper-borne urine for neonatal screening for 21-hydroxylase deficiency: The place of urine in neonatal screening.

Authors:  José Ramón Alonso-Fernández
Journal:  Mol Genet Metab Rep       Date:  2016-08-18

5.  Newborn screening for congenital adrenal hyperplasia in New York State.

Authors:  Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Rhonda Hamel; Breanne Maloney; Daniele-Marisa Stansfield; Emily C McGrath; Amanda Occhionero; Adam Gearhart; Michele Caggana; Norma P Tavakoli
Journal:  Mol Genet Metab Rep       Date:  2016-03-12

6.  Adverse Outcomes and Economic Burden of Congenital Adrenal Hyperplasia Late Diagnosis in the Newborn Screening Absence.

Authors:  Mirela Costa De Miranda; Luciana Bertocco De Paiva Haddad; Guiomar Madureira; Berenice Bilharinho De Mendonca; Tania A S S Bachega
Journal:  J Endocr Soc       Date:  2019-11-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.